Evidence map›Paper›PMID 26614845›Full record

ArticleBosnian journal of basic medical sciences2015

Prognostic significance of survivin, β-catenin and p53 expression in urothelial carcinoma.

Serkan Senol, Asif Yildirim, Bahar Ceyran, Fatih Uruc, Ebru Zemheri, Seyma Ozkanli, Ibrahim Akalin, Ismail Ulus, Turhan Caskurlu, Abdullah Aydin

Open access · diamondAbstract read
In one paragraph

Article in Bosnian journal of basic medical sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Advanced primary urethral cancer: a case report.Journal of medical case reports · 2019
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Serkan SenolMedeniyet Univercity Goztepe Research and Training Hospital Istanbul TURKEY. drserkansenol@gmail.com.
Asif Yildirim
Bahar Ceyran
Fatih Uruc
Ebru Zemheri
Seyma Ozkanli
Ibrahim Akalin
Ismail Ulus
Turhan Caskurlu
Abdullah Aydin
Istanbul Medeniyet University · TRFatih Sultan Mehmet Eğitim Ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Survivin, β-catenin, and p53 are well-known cell-cycle and apoptosis regulators of tumorigenesis. Urothelial carcinomas (UCs) are the most common of the human cancers. Compared to superficial tumors (Ta, CIS, or T1), invasive UCs are important with regard to recurrence, progression, and mortality. Therefore, we examined whether survivin, β-catenin, and p53 could be used as the biomarkers for the early prediction of the invasiveness of UCs and the overall survival of the patients. We investigated the prognostic expressions of those biomarkers in UC (n=147) and in non-muscle invasive UC (NMI-UC) (n=113), using tissue microarray and immunohistochemistry. Spearman's correlation analysis and multivariate Cox regression analyses were used for statistical interpretation. High expressions of β-catenin, survivin, and p53 were associated with a high T stage, recurrence, progression, mortality, low recurrence-free survival, low progression-free survival and low overall survival (p <0.01). Similar findings were achieved for recurrence and progression in the NMI-UC group, except for mortality. Moreover, a positive correlation was shown between p53 and β-catenin and between p53 and survivin (r=0.221, p <0.01; r=0.236, p <0.01, respectively). Survivin, p53, and β-catenin overexpression, as prognostic markers, might suggest that the UCs are biologically aggressive with the poor prognosis. Thus, dysregulation of those these cell-cycle and apoptosis regulators in bladder carcinoma could be used as a molecular marker to determine the best treatment strategy and could contribute to the development of targeted therapies.

Indexed as

AdultAgedAged, 80 and overApoptosis Regulatory Proteinsbeta CateninBiomarkers, TumorDisease-Free SurvivalDisease ProgressionFemaleHumansInhibitor of Apoptosis ProteinsMaleMicroarray AnalysisMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalApoptosis Regulatory Proteinsbeta CateninBiomarkers, TumorBIRC5 protein, humanCTNNB1 protein, humanInhibitor of Apoptosis ProteinsSurvivinTumor Suppressor Protein p53

Identifiers

PMID26614845
PMCPMC4690447
OpenAlexW1854012323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.